PRNewsWire · TOP · November 16, 2026
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: PRNewsWire ↗